The NICB has received over €34.4 research funding from the HEA under the PRTLI Cycle 3 scheme, and has also received funding from SFI, Atlantic Philanthropies, Enterprise Ireland and the Health Research Board. The NICB occupies a unique niche in Ireland's R&D sector in the Irish third-level biomedical sector, applying molecular cell biology research to solving biomedical problems.
The centre, under the Directorship of Professor Martin Clynes, collaborates with a number of Dublin hospitals in the diagnosis and treatment of cancer, diabetes, eye disease and microbial diseases.
The NICB's first cancer drug treatment discovery has been taken into clinical trial with Professor John Crown in St Vincent's Hospital, Dublin. A team of researchers involved in research into resistance to chemotherapy drugs have identified a common arthritis drug, Sulindac, which can inhibit an important cancer resistance factor. Having successfuly completed Phase I of its clinical evaluation, Phase II is currently underway, examining the role of Sulindac in the improvement of the treatment of malignant melanoma. The trial represents the close partnership of scientists in the NICB, clinical researchers and clinicians, the All-Ireland Cooperative Oncology Group and the pharmaceutical industry.
"Although still in the early stages, this unique partnership is a model for the evolution of rational cancer treatment to improve treatments for Irish cancer patients", said Professor Martin Clynes.
Another research project includes the identification of molecular markers which are present in the blood which are indicative of the presence of a cancer and how the cancer is progressing. This new approach, if translated to the clinic, would mean that a standard blood test would allow the clinician to make early diagnosis of cancer even before the onset of systems. Cancers being investigated include breast, lung, pancreatic, renal and skin cancers.
The treatment of corneal blindness is the subject of another research project carried out by the NICB, the Royal Victoria Eye and Ear Hospital, the Irish Blood Transfusion Service and the Blond McIndoe Centre, in the UK. They are examining the molecular markers of corneal stem cells which can be 'grown' in the lab and used to treat a number of corneal diseases and injuries.
The NICB is also involved in a revolutionary new treatment for diabetes which will involve the harvesting of 'islets' from donors and transplanting them directly into the veins patients. These islets then produce insulin normally, bringing about an effective cure to the patients.
As a result of its expertise in mammalian cell culture technology, NICB is also involved in close collaboration with industry, including an SFI-funded €4m collaborative project with Wyeth Biopharma.
Shane Kenny | alfa
Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery
20.01.2017 | GSI Helmholtzzentrum für Schwerionenforschung GmbH
Seeking structure with metagenome sequences
20.01.2017 | DOE/Joint Genome Institute
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
20.01.2017 | Awards Funding
20.01.2017 | Materials Sciences
20.01.2017 | Life Sciences